Fujifulm Kyowa Kirin Biologics

Activities: Drug Delivery

Trending Articles

  1. Merck's MilliporeSigma cuts the ribbon on €290m US biosafety and analytical facility The site will host biosafety testing, analytical development and cell banking manufacturing services
  2. Johnson & Johnson completes V-Wave acquisition to support patients with heart failure The strategic acquisition will bolster the pharma giant's MedTech offerings for patients with cardiovascular disease
  3. Calluna Pharma appoints Mark Gaffney as CEO and Mark Altmeyer as Chair of the Board The two will work to advance the company's global presence, while developing its lead programme
  4. ABITEC Corporation bolsters its high-purity lipid offerings for LNP therapeutics The company can provide cGMP-grade lipids from a mg to a kg scale, assisting the production of advanced LNP therapeutics, including vaccines
  5. Roche's breast cancer combination therapy Itovebi bags FDA approval Itovebi plus palbociclib and fulvestrant reduced the risk of disease progression or death significantly in patients

Upcoming event

ISCC

15-18 October 2024 | Conference | Milan, Italy See all

Related Content

Regulatory

Kyowa Kirin announces approval of topical ophthalmic mitomycin C agent in Japan

This approval is based on the application that Kyowa Kirin had filed in January 2022 for manufacturing and marketing approval
Ingredients

Therapeutic: anticancer agent zandelisib

Phosphatidylinositol 3-kinase delta (PI3K[delta]) is commonly overexpressed in cancer cells. In particular, it plays a vital role in the proliferation and survival of haematologic cancers
Pharmaceutical

Groundbreaking declaratory relief clears the route to market for Humira biosimilars

Fujifulm Kyowa Kirin Biologics (FKB), a biosimilar pharmaceutical company from Japan, has been granted the first ever arrow declaration by UK courts
Subscribe now